COMMUNIQUÉS West-GlobeNewswire

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
02/06/2018
ENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna ® Findings further support durability and safety of TFR with Tasigna; [...]
Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers
02/06/2018
Company to Host Investor Event and Live Webcast on Monday, June 4 CAMBRIDGE, Mass., June 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and [...]
Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting
02/06/2018
– 77% Overall Response Rate in RET Fusion Cancers and 45% Overall Response Rate in RET Mutated Medullary Thyroid Cancer (MTC) – – Activity Observed Independent of RET Alteration, Tumor Type (Lung, Thyroid, Pancreas), or [...]
G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
02/06/2018
RESEARCH TRIANGLE PARK, N.C., June 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 [...]
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
02/06/2018
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of [...]
National Research Corporation Declares Quarterly Dividend
01/06/2018
Lincoln, Nebraska, June 01, 2018 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC)) today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 (seventeen cents) per share [...]
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/06/2018
BURLINGTON, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to eight new employees for an aggregate of 50,000 shares of common stock [...]
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01/06/2018
BOSTON, June 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline [...]
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01/06/2018
EMERYVILLE, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it [...]
FDA Classifies HeartWare(TM) HVAD(TM) Systems Unexpected Power Source Switching as Class I Recall
01/06/2018
DUBLIN - June 1, 2018 - The United States Food and Drug Administration (FDA) has classified Medtronic plc's (NYSE: MDT) recent voluntary urgent field action related to the HeartWare(TM) HVAD(TM) System unexpected power [...]
Reata Selected to Present Early-Stage Programs at the BIO International Convention
01/06/2018
IRVING, Texas, June 01, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that Chief Development Officer, Keith Ward, Ph.D., will present at [...]
Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors
01/06/2018
- Favorable Safety Profile at Dose Levels Below 100 mg; 10 mg and 50 mg Doses Under Evaluation in Recently Initiated Glioma Perioperative Study - - Evidence of Prolonged Disease Control Observed in Non-Enhancing Glioma [...]
OmniSeq and LabCorp Launch OmniSeq Advance℠ Assay
01/06/2018
New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies CHICAGO, June 01, [...]
Xenon Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference
01/06/2018
BURNABY, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer [...]
ArmadaCare Sponsors Live Webinar on Creating a Talent Winning Organization with World-Renowned Business Advisor and Speaker, Ram Charan
01/06/2018
Discover the changes your organization can make to become a talent-driven company. Join Ram Charan at this free online event that’s based on his new book, Talent Wins: The New Playbook for Putting People First, which he [...]
BioSig Technologies to Present at the 8th Annual LD Micro Invitational
01/06/2018
Santa Monica, CA, June 01, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to address an unmet [...]
The Great Canadian Healthcare Debate
01/06/2018
A deeper dive into mental health, Indigenous health and seniors’ health Showdown at St. John’s gathering OTTAWA, June 01, 2018 (GLOBE NEWSWIRE) -- The nation’s health leaders will once again be asked next week to step [...]
Grand débat sur les soins de santé au Canada
01/06/2018
Pleins feux sur la santé mentale, la santé autochtone et la santé des aînés Un choc des idées est à prévoir à St. John’s OTTAWA, 01 juin 2018 (GLOBE NEWSWIRE) -- La semaine prochaine, les leaders en santé du Canada [...]
NICOX : Nulber of voting rights as of May 31, 2018
01/06/2018
Nicox SA Société anonyme with a registered capital of € 29,588,510 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On June 1, 2018, MONTHLY PUBLICATION OF THE [...]

Pages